Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| G-002409 | Other Grant/Funding Number | Barts Charity |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Left Ventricular Thrombus (LVT) is a blood clot that can develop in a poorly functioning heart. In around 1 in 6 patients who have had a heart attack or diagnosed with heart failure tend to develop blood clots in their main heart chamber.
Having a blot clot in the main heart chamber can lead to serious complications such as stroke. Treatment for blood clots is blood thinning medications, which if taken for a prolonged period of time can result in bleeding which further complicates treatment. We hope to gather information to better understand the factors associated with blood clot formation and management in the lower left chamber of the heart. This understanding will hopefully enable us and others to improve management of this condition in the future and therefore help the wider population. As part of this study, bloods and scan results will be recorded and we will complete a short quality of life questionnaire. When participants come in for routine MRI scan, we may capture additional images for further research analysis.
A sample of blood no more than one tablespoon will be collected for research analysis at the same time as routine blood test. This will occur at baseline and at around 6 months. At 12 months we will repeat the quality of life questionnaire and collect final data.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LV Thrombus (present) | Patients with a diagnosis of LV thrombus in the setting of LV dysfunction (acute myocardial infarction, Ischaemic Cardiomyopathy (ICM), dilated cardiomyopathy (DCM)). | ||
| LV Thrombus (at risk) | Patients that do not have LV thrombus but are at risk for developing thrombus such as those with severe LV dysfunction, LV aneurysms, large territory infarcts will also be included. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Composite Result | To measure the composite result of major bleeding (BARC >3), stroke and systemic embolisation, and all-cause mortality | From baseline to final 12 month follow up (+/- 2 months) |
| Measure | Description | Time Frame |
|---|---|---|
| CMR prediction of thrombus | To assess CMR based risk prediction model of recurrence of LV thrombus | From baseline to 6 month follow up (+/- 3 months) |
| Blood Test | To assess blood test variables in the persistence or recurrence of LV thrombus |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with a diagnosis of LV thrombus in the setting of LV dysfunction (acute myocardial infarction, Ischaemic Cardiomyopathy (ICM), dilated cardiomyopathy (DCM)) will be screened. Patients that do not have LV thrombus but are at risk for developing thrombus such as those with severe LV dysfunction, LV aneurysms, large territory infarcts will also be included.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St Bartholomew's Hospital | Recruiting | London | EC1A 7BE | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| From baseline to 6 month follow up (+/- 3 months) |
| Quality of Life Questionnaire | Participants quality of life (QoL) will be measured using European Quality of Life-5 Dimensions - 5 levels (EQ-5D-5L) questionnaire at baseline and 12 months | From baseline to final 12 month follow up (+/- 2 months) |